Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies

The muscular weakness and fatigability associated with myasthenia gravis are engendered by autoantibodies directed against acetylcholine receptors on muscle cells at neuromuscular junctions. The pathogenic consequences of this immune response can potentially be modulated by molecules that bind such...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 1997-01, Vol.15 (1), p.41-45
Main Authors: Lee, Seong-Wook, Sullenger, Bruce A
Format: Article
Language:English
Subjects:
Agriculture
Animals
Antibodies, Monoclonal - drug effects
Antibodies, Monoclonal - metabolism
Autoantibodies - drug effects
Autoantibodies - immunology
Autoimmunity (experimental aspects and models)
Base Sequence
Binding Sites
Bioinformatics
Biological and medical sciences
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Cloning, Molecular - methods
Diseases of striated muscles. Neuromuscular diseases
Down-Regulation - drug effects
Epitopes
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Life Sciences
Medical sciences
Molecular Sequence Data
Myasthenia Gravis - immunology
Neurology
Rats
Receptors, Cholinergic - immunology
Receptors, Cholinergic - metabolism
research-article
Rhabdomyosarcoma - drug therapy
Rhabdomyosarcoma - immunology
Rhabdomyosarcoma - pathology
Ribonucleases - metabolism
RNA - immunology
RNA - metabolism
RNA - pharmacology
Substrate Specificity
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The muscular weakness and fatigability associated with myasthenia gravis are engendered by autoantibodies directed against acetylcholine receptors on muscle cells at neuromuscular junctions. The pathogenic consequences of this immune response can potentially be modulated by molecules that bind such autoantibodies and block their interaction with these receptors. We report the isolation of a small nuclease-resistant RNA molecule that binds both a rat monoclonal antibody that recognizes the main immunogenic region on the acetylcholine receptor, and autoantibodies from patients with myasthenia gravis. Moreover, this RNA can act as a decoy and protect acetylcholine receptors on human cells from the effects of these antibodies.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0197-41